Potential efficacy of local therapy for progressive lesions after nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

• Published in: International journal of clinical oncology 2023-08, Vol.28 (8), p.1023-1032
• Main Authors: Sato, Masanobu, Enokida, Tomohiro, Wada, Akihisa, Okano, Susumu, Tanaka, Hideki, Fujisawa, Takao, Ueda, Yuri, Motegi, Atsushi, Shinozaki, Takeshi, Takeshita, Naohiro, Tanaka, Nobukazu, Zenda, Sadamoto, Matsuura, Kazuto, Akimoto, Tetsuo, Hayashi, Ryuichi, Tahara, Makoto
• Format: Article
• Language: English
• Subjects: Cancer Research; Head & neck cancer; Head and neck carcinoma; Hypopharynx; Immune checkpoint inhibitors; Larynx; Lesions; Medical prognosis; Medicine; Medicine & Public Health; Metastases; Metastasis; Oncology; Oral cavity; Original Article; Oropharynx; Palliation; Patients; Prognosis; Quality of life; Radiation therapy; Squamous cell carcinoma; Surgery; Surgical Oncology
• ISSN: 1341-9625; 1437-7772
• DOI: 10.1007/s10147-023-02351-9

Background In recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), local therapy (LT) such as surgery or radiotherapy can be treatment options for improved survival or quality of life. To date, however, few reports have addressed the efficacy of LT for sites of disease progression after immune checkpoint inhibitors, including other cancers. Methods We conducted a retrospective analysis of patients with R/M SCCHN originating from the oral cavity, oropharynx, hypopharynx, and larynx and treated with nivolumab. We extracted patients undergoing salvage LT or palliative radiotherapy (RT) to the selected progressive lesion at any time after initiation of nivolumab. Results Twenty-four patients received LT. Salvage LT was performed in 9 (37.5%) patients, including surgery and definitive RT in 5 and 4 patients, respectively. Palliative RT was performed in 15 (62.5%) patients. LT was provided in 10 (41.7%) patients for oligoprogressive disease. Twelve (50.0%) patients received subsequent systemic therapy immediately after LT. Classification based on patient treatment divided the population into four subgroups with different prognoses (salvage LT followed by subsequent systemic therapy [ n  = 3], salvage LT alone [ n  = 6], palliative RT followed by subsequent systemic therapy [ n  = 9], and palliative RT alone [ n  = 6]). Median OS in this order was 24.5, 9.0, 7.3, and 2.4 months ( p  = 0.001). All patients in the salvage LT followed by subsequent systemic therapy group continued nivolumab. Conclusion In R/M SCCHN patients who have received nivolumab, salvage LT for the selected progressive lesion with continuation of nivolumab potentially provides an excellent survival prognosis.